Diabetes Fair Scheduled At Exchange

“There are many lifestyle choices that have a tremendous impact on how diabetes will affect one’s life,” said Col. (Dr.) Matthew Wonnacott, 60th Medical Group chief of medical staff at DGMC. “Visiting your Primary Care Manager regularly is very important, especially to arm yourself with credible information, but the most good you can do lies in your day-to-day activities.” According to Wonnacott, the goal of Diabetes Education at DGMC to provide information and education to individuals so they can develop an effective plan to manage diabetes or to delay or prevent its onset. It is important that an individual with diabetes always know the ABCs of diabetes. The hemoglobin A1c level, the blood pressure and the cholesterol levels are important in that these values help to determine how well one is handling their diabetic status.
For the original version including any supplementary images or video, visit http://www.travis.af.mil/news/story.asp?id=123370188

Diabetes increased CAD risk in young, middle-aged women

Research is backed by world-wide clinical trials with over 13,000 participants. SEE RELATED: Hepatitis C will be eradicated starting in weeks Nesina (alogliptin) works by increasing the active incretins enabling the pancreas to secrete insulin in a glucose dependent manner. Oseni combines alogliptin andpioglitazoneto control blood glucose levels. Kazano combines alogliptin and the long time trusted drug metformin HCI in a single tablet which acts primarily by reducing the amount of glucose produced in the liver. Lyxumia (lixisenatide) by Sandofi Pharmaceuticals has been approved in Japan and the European Union for those who cannot control diabetes with exercise and diet and can be taken with or without metformin and basal insulin. Onglyza (saxagliptin) from Bristol-Meyers Squibb/Astrazenica Alliance is for those who cannot take the older standby, metformin.
For the original version including any supplementary images or video, visit http://communities.washingtontimes.com/neighborhood/steps-authentic-happiness-positive-psychology/2013/nov/7/new-drugs-diabetes-types-i-ii/

New drugs for diabetes types I & II

11.22 per 1,000 person-years); MESA (1.66 vs. 5.64 per 1,000 person-years); and NHANES (0.4 vs. 0.88 per 1,000 person-years). CAD events were similar in women with diabetes vs. men with diabetes: GeneSTAR (17.65 vs.
For the original version including any supplementary images or video, visit http://www.healio.com/endocrinology/cardiometabolic-disorders/news/online/{4e1757cb-a088-48de-ae81-2d6c9641f765}/diabetes-increased-cad-risk-in-young-middle-aged-women